Netherlands deals with paediatric SPC extensions
EU legislation on SPCs and paediatric medicines has raised complex questions. Jaap Mannaerts describes how the Dutch IP office and courts have tackled them, and how their approach compares with those of other EU countries
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: